Ligand to Participate in November Investor Conferences
Ligand Pharmaceuticals (Nasdaq: LGND) announced that its senior management team will participate in three investor conferences in November 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ligand Pharmaceuticals (Nasdaq: LGND) announced that its senior management team will participate in three investor conferences in November 2026.
Management will hold investor meetings at the UBS Global Healthcare Conference on November 9 in Palm Beach Gardens and the Miami Biotech Collective Summit on November 30 in Miami. A fireside chat at the Stifel Healthcare Conference is scheduled for November 10 at 10:40 a.m. ET in New York.
Details
News Market Reaction – LGND
On Oct 28, the first trading day after this news, LGND closed 2.26% above the previous close.
Data tracked by StockTitan Argus for the Oct 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences:
- UBS Global Healthcare Conference. Management will participate in one-on-one meetings with investors on November 9, 2026 in Palm Beach Gardens.
- Stifel 2026 Healthcare Conference. Management will participate in a fireside chat on November 10, 2026 at 10:40 a.m. ET in New York.
- Miami Biotech Collective Summit 2026. Management will participate in one-on-one meetings with investors on November 30, 2026 in Miami.
Investors interested in arranging one-on-one meetings should contact their UBS, Stifel, or J.P. Morgan representative.
About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 100 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
